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Abstract 
Vasoconstrictor therapy with terlipressin and concomitant albumin can improve renal function in patients with 
hepatorenal syndrome (HRS) type 1, but the efficacy of therapy in patients with active infection is controversial. The 
aim of this study was to investigate the efficacy, adverse effects, and predictors of terlipressin therapy and to find out 
whether there was a difference in response rates between the patients with or without active infections. Data of 58 
patients with type 1 HRS treated with terlipressin and albumin were retrospectively evaluated. Twenty-six patients 
(44.8 %) showed complete response to treatment. Response rates of patients with or without active bacterial infection 
were 47 and 43.9 %, respectively (p > 0.05). Only baseline serum creatinine level was significantly related to response 
in univariate/multivariate analyses (p < 0.05). Twenty-three patients (39.6 %) developed adverse effects probably 
related to treatment. In 8.6 % of patients, treatment was discontinued because of adverse effects of therapy. Four 
patients (6.9 %) developed ischemic adverse events, including nonfatal myocardial infarction, intestinal ischemia, and 
cutaneous necrosis. Terlipressin plus albumin therapy improved renal function in nearly half of patients with type 1 
HRS. Thus, it seems a reasonable treatment for patients with active bacterial infections. Baseline serum creatinine level 
is a potential predictor of terlipressin response.
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Background
Hepatorenal syndrome (HRS) is a potentially revers-
ible, functional renal failure that occurs in patients with 
advanced liver disease. HRS is generally characterized by 
increased serum creatinine, azotemia, reduced diuresis, 
increased urine osmolarity, and reduced urine sodium 
values without signs of organic kidney damage (Salerno 
et al. 2007).
Vasoconstrictor therapy with terlipressin (a vaso-
pressin-V1 receptor agonist), and concomitant albumin 
can improve renal function in patients with type 1 HRS 
(Ortega et  al. 2002; Solanki et  al. 2003; Martín-Llahi 
et  al. 2008; Sanyal et  al. 2008; Neri et  al. 2008). Terli-
pressin seems to reverse the systemic and splanchnic 
vasodilatation, increase blood pressure, and decrease the 
hepatic-renal arterial resistance in cirrhotic patients with 
and without ascites (Narahara et al. 2009).
Many studies, including several randomized controlled 
trials, have shown that terlipressin is associated with 
a low incidence of adverse effects (Ortega et  al. 2002; 
Solanki et al. 2003; Martín-Llahi et al. 2008; Sanyal et al. 
2008; Neri et al. 2008; Moreau et al. 2002; Mulkay et al. 
2001; Halimi et al. 2002). In the recent guidelines, a start-
ing terlipressin dose of 0.5–1.0 mg/4–6 h by IV bolus has 
been recommended (Salerno et al. 2007). However, many 
unanswered questions remain regarding the optimal 
dose, optimal route of administration, and the potential 
adverse effects, including severe ischemic events.
According to the revised diagnostic criteria reported 
in 2007, patients with renal failure and active bacterial 
infections, without septic shock, are also considered as 
having HRS. Additionally, in the recent guidelines, start-
ing the treatment of HRS before a complete recovery 
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from the infection has been recommended (Salerno et al. 
2007).
In this article, we have investigated a cohort of subjects 
with liver cirrhosis who fulfill the criteria of type 1 HRS 
according to the guidelines used at the time of diagno-
sis. The primary aim of this study was to investigate the 
efficacy, possible adverse effects, and potential predic-
tors of terlipressin therapy. The secondary aim was to 
find out whether there was a difference in terms of com-
plete response to treatment with terlipressin between the 
patients with or without active infections.
Methods
Data of 58 patients meeting the criteria of type 1 HRS, 
as proposed by the International Ascites Club at the time 
of diagnosis (Salerno et al. 2007; Arroyo et al. 1996), who 
underwent treatment with terlipressin at our hospital, 
were retrospectively reviewed. The protocol of this study 
was in accordance with ethical standards of Baskent Uni-
versity research committee and patients provided written 
informed consent to participate in the study.
All patients with suspected HRS were evaluated with 
the protocol that includes diuretic withdrawal, assess-
ment of other possible causes of prerenal azotemia, and 
a trial of plasma expansion with albumin. To rule out 
renal parenchymal diseases, urine analyses and abdomen 
ultrasonography were performed. The presence of infec-
tion was evaluated with blood, sputum, urine, and ascitic 
fluid cultures as well as serum, and ascitic fluid leukocyte 
counts, serum C-reactive protein levels, and chest radio-
graphs. In all patients, cultures were routinely obtained 
before the start of antibiotic therapy. Patients who ful-
filled the criteria of type 1 HRS according to the guide-
lines used at the time of diagnosis were treated (Salerno 
et al. 2007; Arroyo et al. 1996). Thirty of 58 patients were 
diagnosed and managed based on previous criteria since 
the new criteria had yet to be published at that time. In 
17 of the 28 patients diagnosed with the new criteria, an 
active bacterial infection was present. Ten of 17 patients 
had spontaneous bacterial peritonitis (presence of a pol-
ymorphonuclear leucocyte count >250/mm3 in ascitic 
fluid, with or without positive culture). Other infections 
were as follows: three patients with bacterial pneumo-
nia, three patients with urinary tract infection, and one 
patient with spontaneous bacteremia (presence of posi-
tive blood cultures without evident source of infection).
The exclusion criteria were as follows: presence of 
severe extrahepatic condition, including cardiovascular 
(coronary and/or peripheral arterial disease) and neuro-
logical diseases, septic shock, and hepatocellular carci-
noma outside the Milan criteria.
All patients were hospitalized in the intensive care 
unit before therapy. Before therapy with terlipressin, all 
patients were monitored noninvasively. Arterial pres-
sure and urinary output were checked every 4 h. Cardiac 
rhythm was monitored continuously. An electrocardio-
gram was performed before and during treatment when 
needed. Patients with cardiac symptoms, and typical 
signs of ischemia on the first electrocardiogram were not 
included the study. All patients had an echocardiographic 
study within the 6 months period before treatment. Phys-
ical examination and routine laboratory tests were per-
formed in all patients before the initiation of therapy and 
daily intervals during treatment.
During the first 3  days of treatment, terlipressin (gly-
pressin 1 mg; Ferring GmbH, Kiel, Germany) was admin-
istered at a dose of 0.5–1 mg every 4 h as an intravenous 
bolus in 50 patients and as a short-period infusion (15–
30 min) in eight patients. If after the first 3 days, serum 
creatinine decreased at least 25  % of the pretreatment 
values, the dose remained unchanged. In patients whose 
serum creatinine did not decrease at least 25  % of the 
pretreatment values within the first 3 days, the dose was 
increased up to a maximum of 2 mg/4 h. Terlipressin was 
given until serum creatinine decreased below 1.5  mg/dl 
and urine output increased above 500 ml/day. We did not 
use a fixed maximum time period for terlipressin treat-
ment. Patients received 40 g of albumin during the first 
24 h, followed by 20 g/day. Patients with proven bacterial 
infection were treated with wide-spectrum antibiotics 
including second- and third-generation cephalosporins 
and carbapenems according to antimicrobial susceptibil-
ity. Prophylactic antibiotic therapy was not given during 
the treatment.
Severity of liver disease was assessed by the Child–
Pugh classification. Patients were followed until death, 
discharge, or liver transplantation. Patients developing 
recurrence were not evaluated again. Adverse effects of 
therapy were also recorded.
Statistical analysis
Results are presented as mean ± standard deviation (SD) 
and median (minimum–maximum). Continuous vari-
ables were compared with Student’s t test, and Mann–
Whitney test. Categorical variables were compared with 
Pearson Chi square and Fisher’s exact tests. Univariate 
and multivariate logistic regression analyses were per-
formed to identify predictors of response. A p < 0.05 was 
considered as statistically significant. All analyses were 
done using the Statistical Package for the Social Sciences 
(SPSS) 19.0 (SPSS Inc. Chicago, IL, USA).
Results
Data of 58 patients with type 1 (HRS), who underwent 
treatment with terlipressin and albumin, were evaluated. 
Among 58 patients, 77.6 % (n = 45) and 22.4 % (n = 13) 
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were men and women, respectively. Patients had a mean 
age of 52.6 ± 10.6 years. Cirrhosis was caused by viral hepa-
titis (28 patients with hepatitis B, 6 patients with delta hep-
atitis, and 2 patients with hepatitis C) in 62.1 % (n = 36) of 
patients. Severity of cirrhosis defined by Child–Pugh score 
was Class A in 6.9 % (n = 4), Class B in 27.6 % (n = 16), and 
Class C in 65.5 % (n = 38). Ascites was present in 87.9 % 
(n = 51) of patients. Demographic and clinical characteris-
tics of the patients before therapy are shown in Table 1.
Twenty-six patients (44.8  %) showed response to the 
treatment. Demographic and clinical characteristics 
of responders and nonresponders are summarized in 
Table 2. Of note, in 11 of 27 patients who did not show 
response to the treatment, the 24  h urine volume was 
increased over 500  ml/day during treatment. Baseline 
serum creatinine was significantly low, and 24  h urine 
volume was significantly high in responders compared 
with nonresponders (p < 0.05).
Seventeen of the 58 patients (29.3  %) had an active 
bacterial infection, without septic shock. In the group 
of patients with HRS and active bacterial infection, 8 of 
17 patients (47 %) showed response treatment with ter-
lipressin and albumin, while 18 of 41 patients (43.9  %) 
without active infection showed response (p > 0.05).
The variables, age, gender, etiology of cirrhosis, Child–
Pugh scores, existence of ascites, existence of active 
bacterial infection, serum total bilirubin, serum albu-
min, serum creatinine, serum sodium levels, 24  h urine 
volume, and mean arterial pressure (MAP) were evalu-
ated as potential predictors of terlipressin and albumin 
response in both univariate and multivariate analyses 
(Table 3). Only baseline serum creatinine level (<2.5 mg/
dl) was significantly related to response (p < 0.05).
Twenty-three patients (39.6 %) developed adverse effects 
probably related to the treatment, and in 5 of 58 patients 
(8.6 %), treatment was discontinued because of treatment-
emergent adverse effects. Sixteen patients (27.6 %) devel-
oped diarrhea, which subsided after cessation (1 patient), 
lowering dose (3 patients), or changing administration 
protocol to short-period infusion (12 patients) of terlipres-
sin therapy. Three patients (5.2  %) developed abdominal 
pain, which subsided after changing administration proto-
col to short-period infusion (one patient) or lowering dose 
(two patients) of terlipressin therapy. Four patients (6.9 %) 
developed ischemic adverse events (myocardial infarction, 
intestinal ischemia, cutaneous necrosis). In one patient 
with cutaneous necrosis and two patients with intestinal 
ischemia, symptoms disappeared after terlipressin with-
drawal. Finally, one patient developed nonfatal myocardial 
infarction during terlipressin therapy.
HRS recurred in 12 (46.1  %) of 26 patients who 
responded to treatment. Mean survival time was signifi-
cantly greater in responders compared with nonrespond-
ers (42 ± 6.2 and 21.8 ± 4.3 days, respectively, p < 0.05). 
Five patients had undergone transplantation. The trans-
plant-free survival at 15 and 30  days of treatment was 
54.7 and 32 %, respectively.
Discussion
Splanchnic vasodilation in cirrhotic patients may reduce 
effective arterial filling, resulting in renal vasoconstruc-
tion (Moller and Henriksen 2004). Intravascular volume 
Table 1 Demographic and clinical characteristics of the 58 
patients
MAP mean arterial pressure
a Mean ± SD
Agea (years) 52.6 ± 10.6
Gender (M/F) 45/13
Child–Pugh class (A/B/C) 4/16/38
Etiology (viral hepatitis/others) 36/22
Ascites (±) 51/7
Active bacterial infection (±) 17/41
Serum total bilirubina (mg/dl) 2.8 ± 0.8
Serum albumina (g/dl) 2.7 ± 0.6
Serum creatininea (mg/dl) 2.2 ± 0.8
Serum Naa (mEq/L) 129 ± 5
Urine volumea (ml/day) 339 ± 190
MAPa (mmHg) 78 ± 9
Table 2 Demographic and  clinical characteristics 
of responders and nonresponders before therapy
NS nonsignificant, MAP mean arterial pressure
a Mean ± SD
Responders 
(n = 26)
Nonresponders 
(n = 27)
p
Agea(years) 53.9 ± 7.7 53 ± 11.4 NS
Gender (M/F) 19/7 24/3 NS
Etiology of cirrhosis 
(viral hepatitis/ 
others)
18/8 16/11 NS
Child–Pugh class 
(A/B/C)
3/7/16 1/7/19 NS
Child–Pugh score 9.8 ± 2.5 10.2 ± 2 NS
Ascites (±) 22/4 25/2 NS
Active bacterial infec-
tion (±)
8/18 7/20 NS
Serum total bilirubina 
(mg/dl)
2.6 ± 0.8 2.9 ± 0.8 NS
Serum albumina (g/dl) 2.6 ± 0.6 2.7 ± 0.5 NS
Serum creatininea 
(mg/dl)
1.9 ± 0.4 2.5 ± 1 <0.05
Serum Naa (mEq/L) 129 ± 6 128 ± 4 NS
Urine volumea  
(ml/day)
400 ± 186 285 ± 181 <0.05
MAPa (mmHg) 80 ± 10 77 ± 9 NS
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expansion with vasoconstrictor drugs may reverse this 
vicious cycle and contribute to the treatment of patients 
with HRS or at risk of HRS (Krag et  al. 2007). The 
achievement of optimal volume expansion is difficult in 
these patients with standard static hemodynamic meas-
urements (Marik et  al. 2008). Volume overload should 
be avoided owing to the risk of expanding third spaces 
and the subsequent development of abdominal com-
partment syndrome, which could reduce renal perfusion 
(Dalfino et al. 2008). Studies have shown that the use of 
vasocontrictors, such as noradrenaline and terlipressin 
in conjunction with albumin, improves renal function 
in patients with HRS compared with the use of vasocon-
strictors or albumin alone (Ortega et  al. 2002; Solanki 
et  al. 2003; Martín-Llahi et  al. 2008; Sanyal et  al. 2008; 
Neri et  al. 2008; Sharma et  al. 2008). Randomized con-
trolled studies have shown that the HRS reversal rates 
achieved with terlipressin and albumin treatment ranged 
between 34 and 81 % (Sanyal et al. 2008; Neri et al. 2008). 
The reason of this wide spectrum may be due to both 
complexity of the pathogenesis and difficulties in the 
assessment of effective treatment. In our study, simi-
lar to many randomized controlled trials (Solanki et  al. 
2003; Martín-Llahi et al. 2008), 44.8 % of patients showed 
response to treatment.
According to the 2007 consensus report, patients with 
renal failure and active bacterial infections, without 
septic shock, are also diagnosed as having HRS. Addi-
tionally, starting the treatment before a complete recov-
ery from the infection has been recommended (Salerno 
et  al. 2007). The results of the study published by Bar-
reto et  al. in 2014 has supported this recommendation. 
They showed that type 1 HRS associated with infections 
is not reversible in two-thirds of patients with treatment 
of infection only (Barreto et  al. 2014). This result has 
pointed to the terlipressin and albumin treatment again. 
The gap in the knowledge of type 1 HRS associated with 
infection has filled with the study of Rodriguez et  al. 
Their study provides evidence indicating that terlipressin 
and albumin is also effective for the treatment of type 1 
HRS associated with sepsis (Rodriguez et al. 2014).
In our study, we also compared groups of patients with 
or without active infection and found that there is no 
statistically significant difference between HRS reversal 
rates (47 and 43.9 %, respectively, p > 0.05) as mentioned 
by Rodriguez et al. 2014. In many patients, type 1 HRS is 
triggered by bacterial infections given the aggravation of 
splanchnic vasodilatation by endotoxemia and cytokine 
overproduction (Arroyo et  al. 2007). As shown in our 
study, it seems reasonable to treat these patients with ter-
lipressin and albumin concomitantly with antibiotics.
Predictors of response to terlipressin and albumin 
therapy in patients with type 1 HRS in previous studies 
included baseline Child–Pugh and MELD scores, serum 
creatinine, serum bilirubin levels, 24  h urine volume, 
and the presence of an increase in MAP during therapy 
(Sanyal et al. 2008; Neri et al. 2008; Moreau et al. 2002; 
Boyer et al. 2011; Nazar et al. 2010). In our study, base-
line serum creatinine was significantly low, and urine 
volume was significantly high in responders, whereas 
significant differences did not exist in terms of age, sex, 
serum bilirubin, serum albumin, serum sodium levels, 
Table 3 Univariate analysis for potential predictors of ter-
lipressin and concomitant albumin response
CI confidence interval, OR odds ratio
a MAP mean arterial pressure
Variables OR (95 % CI) p
Age
 >50 2.0 (0.67–5.98) 0.21
 ≤50
Gender
 Male 2.9 (0.67–12.9) 0.15
 Female
Etiology of cirrhosis
 Viral hepatitis 1.5 (0.49–4.80) 0.45
 Others
 Child–Pugh score
  ≤10 1.7 (0.57–5.05) 0.33
  >10
 Ascites
  Yes 2.2 (0.37–13.63) 0.36
  No
 Active bacterial infection
  Yes 1.2 (0.38–4.20) 0.69
  No
 Serum total bilirubin (mg/dl)
  ≤3 2.0 (0.67–5.98) 0.21
  >3
 Serum albumin (g/dl)
  ≥2.8 1.51 (0.49–4.57) 0.46
  <2.8
 Serum creatinine (mg/dl)
  <2.5 6.13 (1.47–25.44) 0.01
  ≥2.5
 Serum Na (mEq/L)
  ≥130 2.45 (0.76–7.88) 0.13
  <130
 Urine volume (ml/day)
  ≥400 2.33 (0.76–7.08) 0.13
  <400
 MAPa (mmHg)
  ≥80 2.31 (0.77–6.98) 0.13
  <80
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and baseline MAP between responders and nonrespond-
ers. In a recent study (Boyer et al. 2011), it was reported 
that the most consistent predictor of response was base-
line serum creatinine as observed in our study. Mean-
while, baseline serum creatinine was not associated with 
response in another study (Nazar et al. 2010). We think 
that predictors of response to terlipressin therapy are not 
well established in the literature, and further studies are 
needed.
Terlipressin has a low adverse effect profile compar-
ing to other vasopressors that have been used for the 
treatment of HRS. However, it is recommended that 
terlipressin be used in an intensive care unit with close 
hemodynamic monitoring because of potentially serious 
ischemic adverse events (European association for the 
study of the liver 2010). In a randomized controlled trial 
including 112 patients with type 1 HRS, it was reported 
that serious adverse effects were mostly cardiovascular 
and were observed in 9 % of patients treated with terli-
pressin and albumin. For this reason, in that study, treat-
ment was discontinued in 5.4 % of patients (Sanyal et al. 
2008). In another randomized controlled trial, cardio-
vascular complications occurred in 22 % of patients, but 
terlipressin therapy was discontinued in only one patient 
because of high blood pressure (Martín-Llahi et al. 2008). 
By comparison, a meta-analysis including 10 clinical tri-
als, published before these two abovementioned trials 
reported that the pooled rate of withdrawal, and adverse 
effects of terlipressin therapy were 0 and 29  %, respec-
tively. In our study, 39.6 % of patients developed adverse 
effects related to treatment, and in 8.6  % of patients, 
treatment was discontinued. These adverse effects were 
diarrhea (27.6 %), abdominal pain (5.2 %), and ischemic 
adverse events (6.9  %), including nonfatal myocardial 
infarction, intestinal ischemia, and cutaneous necro-
sis. Other adverse effects reported before, such as car-
diac arrhythmias, hypertension, respiratory failure, and 
bronchospasm, were not observed. Further, none of our 
patients died because of terlipressin therapy.
In our study, adverse effects related to terlipressin ther-
apy occurred after a mean of 2.6 days. Thus, it should be 
emphasized that close monitoring for adverse effects is 
required during the first few days of treatment, in par-
ticular, when treating patients with comorbidities.
Some authors suggest that continuous terlipressin 
infusion may have less severe adverse effects with the 
same response rates compared with intermittent IV 
bolus administration (Gerbes et al. 2009). However, this 
hypothesis has not been proven in any randomized, con-
trolled trials yet. In our study, terlipressin was admin-
istered initially as an IV bolus in 50 patients, and as 
short-period infusion (15–30 min) in eight patients. We 
did not compare the groups in terms of adverse effects 
because of the small number of patients. However, 
adverse effects subsided after changing the administra-
tion protocol from IV bolus to short-period infusion in 
56.5  % of patients who developed adverse effects. Thus, 
it should be noted that short-period infusion may be 
an alternative of IV bolus administration if the onset of 
adverse events occurs.
Our study has some limitations. First, it is a retrospec-
tive study with a relatively small number of patients. 
Moreover, predictive factors of response should be ana-
lyzed in a prospective study.
In conclusion, our study results indicate that terli-
pressin plus albumin therapy improves renal function 
in nearly half of patients with type 1 HRS. Further, it is 
reasonable to treat patients with type 1 HRS and active 
bacterial infections because of similar response rates 
compared with patients without active infections. Nev-
ertheless, clinicians should be vigilant for severe adverse 
effects. We think that future studies should be focused 
on predictors of response to terlipressin therapy and 
therapies for prophylaxis as well as new pharmacological 
agents for nonresponders.
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